Standard Contracts
ContractExclusive License and Collaboration Agreement • September 17th, 2021
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT between HUTCHISON MEDIPHARMA LIMITED and ELI LILLY TRADING (SHANGHAI) COMPANY LIMITED and HUTCHISON CHINA MEDITECH LIMITEDExclusive License and Collaboration Agreement • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations
This Agreement (the “Agreement”), effective as of 8th October 2013 (the “Effective Date”), is entered into by and among (i) Hutchison MediPharma Limited, a Chinese company, organized and existing under the laws of the People’s Republic of China, having a place of business at Building 4, 720 Cai Lun Road, ZJ Hi-Tech Park, Shanghai, PRC (“Hutchison”) and (ii) Eli Lilly and Company, an U.S.A. company, organized and existing under the laws of the State of Indiana, having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 U.S.A. (“Lilly”), and (iii) solely for the purposes of Articles 7.11(a), 7.11(b) and 7.11(c), Hutchison China MediTech Limited, a company organized and existing under the laws of the Cayman Islands with its principal offices at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (the “Hutchison Guarantor”). Hutchison and Lilly may be referred to herein individually as a “Party” or collectively as the “Parties.” Reference to a Party shal
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED AMENDED AND RESTATED...Exclusive License and Collaboration Agreement • May 30th, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations
This Agreement (the “Agreement”), effective as of 8th October 2013 (the “Effective Date”), is entered into by and among (i) Hutchison MediPharma Limited, a Chinese company, organized and existing under the laws of the People’s Republic of China, having a place of business at Building 4, 720 Cai Lun Road, ZJ Hi-Tech Park, Shanghai, PRC (“Hutchison”) and (ii) Eli Lilly and Company, an U.S.A. company, organized and existing under the laws of the State of Indiana, having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 U.S.A. (“Lilly”), and (iii) solely for the purposes of Articles 7.11(a), 7.11(b) and 7.11(c), Hutchison China MediTech Limited, a company organized and existing under the laws of the Cayman Islands with its principal offices at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (the “Hutchison Guarantor”). Hutchison and Lilly may be referred to herein individually as a “Party” or collectively as the “Parties.” Reference to a Party shal
Exclusive License and Collaboration AgreementExclusive License and Collaboration Agreement • November 20th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT IS ENTERED INTO EFFECTIVE AS OF AUGUST 06, 2012 (THE ‘‘EFFECTIVE DATE”) BETWEEN:
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • February 28th, 2014 • Mymetics Corp • Biological products, (no disgnostic substances) • New York
This Exclusive License and Collaboration Agreement (this “Agreement”) is entered into as of the 27th day of December, 2013 (the “Effective Date”) by and between RSV Corporation, a corporation organized under the laws of Delaware, with its principal place of business at 7361 Calhoun Place, Suite 510, Rockville, MD 20855, USA (“RSVC”), and Bestewil Holding B.V., a company organized and existing under the laws of the Netherlands, with a principal business address at J.H. Oortweg 21, 2333 CH Leiden, The Netherlands (“BH”).
Windtree Therapeutics and Lee’s Pharmaceutical (HK) Limited Enter Into Exclusive License and Collaboration Agreement for Development and Commercialization of KL4 Surfactant Technology Platform in AsiaExclusive License and Collaboration Agreement • June 13th, 2017
WARRINGTON, PA and SHATIN, HONG KONG – June 12, 2017 – Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm", SEHK Stock Code: 0950), today announced that they have entered into an exclusive license and collaboration agreement for the development and commercialization of KL4 surfactant products in select Asian markets using Windtree’s proprietary KL4 surfactant and aerosolization technologies. The agreement includes AEROSURF® as well as the non-aerosol products SURFAXIN® (approved in the U.S.) and SURFAXIN LS (an improved lyophilized formulation of SURFAXIN). Also, Windtree has granted Lee’s an exclusive license to manufacture KL4 surfactant in China for use in non-aerosol surfactant products in the licensed territory.
Amendment #1 to the Exclusive License and Collaboration AgreementExclusive License and Collaboration Agreement • November 20th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations
EX-10.18 4 d892618dex1018.htm EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT * Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant...Exclusive License and Collaboration Agreement • May 5th, 2020 • Pennsylvania
THIS EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) dated as of May 3, 2016 (the “Effective Date”), is entered into between The Trustees of the University of Pennsylvania (“Licensor” or “Penn”), and Audentes Therapeutics, Inc., a Delaware corporation (“Company”), having a place of business located at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA, each a “Party” and collectively “Parties”.
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • November 22nd, 2022 • Health Sciences Acquisitions Corp 2 • Surgical & medical instruments & apparatus • New York
This EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (“Agreement”) is entered into as of June 30, 2022 (the “Effective Date”) by and between Orchestra Biomed, Inc., a Delaware corporation with a principal place of business at 150 Union Square Drive New Hope, PA 18938 (“Orchestra Biomed”), BackBeat Medical, LLC, a Delaware limited liability company and wholly-owned subsidiary of Orchestra Biomed with a principal place of business at 150 Union Square Drive New Hope, PA 18938 (“BackBeat”, together with Orchestra Biomed, “Orchestra”), and Medtronic, Inc., a Minnesota corporation with a principal place of business at 710 Medtronic Parkway, Minneapolis, Minnesota 55432 (“Medtronic”). Orchestra and Medtronic are referred to each as a “Party” or collectively as the “Parties”.
Amended and Restated Exclusive License and Collaboration AgreementExclusive License and Collaboration Agreement • May 3rd, 2017 • Cti Biopharma Corp • Pharmaceutical preparations • England and Wales
LES LABORATOIRES SERVIER, a company duly organized and existing under the laws of France, having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France
DATE: DECEMBER 7, 2005Exclusive License and Collaboration Agreement • March 7th, 2006 • Critical Therapeutics Inc • Pharmaceutical preparations • Delaware
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • June 30th, 2016 • Atomera Inc • Semiconductors & related devices • Massachusetts
This Exclusive License and Collaboration Agreement (“Agreement”) is made and entered into this 3rd day of March, 2010 (the “Effective Date”), by and between Mears Technologies, Inc., a Delaware corporation with its principal offices at 1100 Winter Street, Suite 4700, Waltham, MA 02451 (“Licensor”) and K2 Energy Limited, a corporation with its principal offices at Level 2, 27 Macquarie Place, Sydney NSW 2000, Australia (“Licensee”).
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 11th, 2008 • GTX Inc /De/ • Pharmaceutical preparations • Delaware
This Exclusive License and Collaboration Agreement (this “Agreement”) is made and entered into effective as of the Closing Date (defined below) and is entered into by and between Merck & Co., Inc., a corporation organized and existing under the laws of New Jersey (“Merck”), and GTx, Inc., a corporation organized and existing under the laws of Delaware (“GTx”).
ContractExclusive License and Collaboration Agreement • July 13th, 2021
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
THIRD AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • August 10th, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances)
This THIRD AMENDMENT (“Third Amendment”) is entered into as of July 14, 2017 (the “Third Amendment Effective Date”) by and between Audentes Therapeutics Inc., having its principal offices at 600 California Street, 17th Floor, San Francisco, CA 94108 (“Audentes”), and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6228 (“Penn”). Audentes and Penn are referred to collectively as the “Parties” and individually as a “Party.”
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • June 24th, 2020 • Renalytix AI PLC • Services-medical laboratories • New York
THIS EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) dated as of May 30, 2018 (“Effective Date”), is entered into between ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, a New York not-for-profit education corporation (“ISMMS”), with a place of business at One Gustave L. Levy Place, New York, New York 10029, and RENALYTIX AI, plc., a United Kingdom public limited company (“RenalytixAI”), having a place of business at Avon House, 19 Stanwell Road, Penarth, Cardiff, UK CF64 2EZ.
THIRD AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • August 9th, 2010 • Intermune Inc • Pharmaceutical preparations
This Third Amendment (this “Amendment”) to the Exclusive License and Collaboration Agreement effective as of October 16, 2006 (“Original Agreement,” as amended by that certain First Amendment effective as of October 16, 2008 (“First Amendment”) and that certain Second Amendment effective as of October 16, 2009 (“Second Amendment”) (the Original Agreement, as amended by the First Amendment and the Second Amendment, the “Agreement”) is made effective as of April 30, 2010 (the “Third Amendment Effective Date”) and entered into by and between Hoffmann-La Roche Inc., a New Jersey corporation located at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche Nutley”), and F.Hoffmann-La Roche Ltd, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (“Roche Basel”; Roche Nutley and Roche Basel are collectively referred to as “Roche”), on the one hand, and InterMune, Inc., a Delaware corporation with its principal place of business at 3280 Bayshore
FIRST AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 16th, 2009 • Intermune Inc • Pharmaceutical preparations
This First Amendment (this “Amendment”) to the Exclusive License and Collaboration Agreement effective as of October 16, 2006, (the “Agreement”) is made effective as of October 16, 2008 (the “Amendment Effective Date”) and entered into by and between Hoffmann-La Roche Inc., a New Jersey corporation located at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche Nutley”), and F.Hoffmann-La Roche Ltd, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (“Roche Basel”; Roche Nutley and Roche Basel are collectively referred to as “Roche”), on the one hand, and InterMune, Inc., a Delaware corporation with its principal place of business at 3280 Bayshore Boulevard, Brisbane, California 94005 (“InterMune”), on the other hand.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT (INDICATED BY [***]) HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS PRIVATE OR CONFIDENTIAL....Exclusive License and Collaboration Agreement • September 27th, 2022 • Inventiva S.A. • Pharmaceutical preparations
This Exclusive License and Collaboration Agreement (the “Agreement”) is entered into as of September 21, 2022 (the “Effective Date”), by and between Inventiva S.A., a company incorporated under the laws of France, having its principal place of business at 50, rue de Dijon à Daix (21121), France (“Inventiva”), and Chia Tai Tianqing Pharmaceutical Group, Co., Ltd., a limited liability company incorporated and existing under the laws of the People’s Republic of China, having its registered office located at No.369 South Yuzhou RD., HaiZhou District, Lianyungang, Jiangsu Province, Mainland China (“Licensee”).
AMENDMENT No. 2 to the Exclusive License and Collaboration Agreement between Novartis Pharma AG and Amgen Inc.Exclusive License and Collaboration Agreement • July 26th, 2017 • Amgen Inc • Biological products, (no disgnostic substances)
This Amendment No. 2 (“Amendment”) is entered into as of April 21, 2017 (“Amendment No. 2 Effective Date”) by and between Novartis Pharma AG a Swiss corporation having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”) and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA (“Amgen”). Novartis and Amgen are each referred to individually as a “Party” and together as the “Parties”.
SECOND AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 4th, 2021 • Hutchison China MediTech LTD • Pharmaceutical preparations
This Second Amendment (this "Second Amendment") to the Amended and Restated Exclusive License and Collaboration Agreement, effective as of October 8, 2013 and amended by the First Amendment effective as of December 18, 2018 (the "First Amendment"), and made by and between
SECOND AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 15th, 2010 • Intermune Inc • Pharmaceutical preparations
This Second Amendment (“Second Amendment”) to the Exclusive License and Collaboration Agreement effective as of October 16, 2006 (as amended by that certain First Amendment effective as of October 16, 2008 (“First Amendment”)) (collectively, the “Agreement”) is made effective as of October 16, 2009 (the “Second Amendment Effective Date”) and entered into by and between Hoffmann-La Roche Inc., a New Jersey corporation located at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche Nutley”), and F.Hoffmann-La Roche Ltd, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (“Roche Basel”; Roche Nutley and Roche Basel are collectively referred to as “Roche”), on the one hand, and InterMune, Inc., a Delaware corporation with its principal place of business at 3280 Bayshore Boulevard, Brisbane, California 94005 (“InterMune”), on the other hand.
FIRST AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • May 2nd, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations
This First Amendment (this “Amendment”) to the Amended and Restated Exclusive License and Collaboration Agreement, effective as of October 8, 2013 and made by and between
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 30th, 2007 • Intermune Inc • Pharmaceutical preparations • Delaware
This Exclusive License and Collaboration Agreement (this “Agreement”) is executed as of October 16, 2006, (the “Execution Date”) and effective as of the Effective Date and is entered into by and between Hoffmann-La Roche Inc., a New Jersey corporation located at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche Nutley”), and F.Hoffmann-La Roche Ltd, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (“Roche Basel”; Roche Nutley and Roche Basel are collectively referred to as “Roche”), on the one hand, and InterMune, Inc., a Delaware corporation with its principal place of business at 3280 Bayshore Boulevard, Brisbane, California 94005 (“InterMune”), on the other hand.
FIRST AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 13th, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT (“First Amendment”) is entered into as of December 21, 2016 (the “First Amendment Effective Date”) by and between Audentes Therapeutics Inc., having its principal offices at 600 California Street, 17th Floor, San Francisco, CA 94108 (“Licensor”), and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6228 (“Institution”). Licensor and Institution are sometimes hereinafter referred to collectively as the “Parties” and individually as a “Party.”
FOURTH AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 9th, 2018 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances)
This FOURTH AMENDMENT (“Fourth Amendment”) is entered into as of December 20th, 2017 (the “Fourth Amendment Effective Date”) by and between Audentes Therapeutics Inc., having its principal offices at 600 California Street, 17th Floor, San Francisco, CA 94108 (“Audentes”), and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6228 (“Penn”). Audentes and Penn are referred to collectively as the “Parties” and individually as a “Party.”
AMENDMENT No 4 TO THE EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • October 15th, 2024 • Inventiva S.A. • Pharmaceutical preparations
This FOURTH AMENDMENT TO THE EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this “Amendment #4”) is entered into as of October 11th, 2024 (the “Amendment #4 Effective Date”) by and between:
Merck, Kelun-Biotech ink $9.3 B licensing pact for seven cancer candidates in ChinaExclusive License and Collaboration Agreement • December 29th, 2022
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 28th, 2008 • Transition Therapeutics Inc. • Medicinal chemicals & botanical products
This Agreement (the “Agreement”), effective as of March 13th , 2008 (the “Effective Date”), is entered into by and among Waratah Pharmaceuticals Inc., a Canadian corporation, with a place of business at 101 College Street, Suite 220, Toronto, Ontario, M5G 1L7, a wholly owned subsidiary of Transition Therapeutics Inc., (hereinafter collectively referred to as “Transition”) and Eli Lilly and Company, an Indiana corporation with a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”). Transition and Lilly may be referred to herein individually as a “Party” or collectively as the “Parties.” Reference to a Party shall be deemed to include that Party’s Affiliates.
SECOND AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • April 3rd, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT (“Second Amendment”) is entered into as of March 21, 2017 (the “Second Amendment Effective Date”) by and between Audentes Therapeutics Inc., having its principal offices at 600 California Street, 17th Floor, San Francisco, CA 94108 (“Audentes”), and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6228 (“Penn”). Audentes and Penn are referred to collectively as the “Parties” and individually as a “Party.”
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN AMGEN INC. AND NOVARTIS PHARMA AGExclusive License and Collaboration Agreement • July 26th, 2017 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Exclusive License and Collaboration Agreement (this “Agreement”), effective as of August 28, 2015 (the “Effective Date”), is by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, U.S.A. (“Amgen”), and Novartis Pharma AG, a Swiss company having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Amgen and Novartis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT between CIDARA THERAPEUTICS, INC. and JANSSEN PHARMACEUTICALS, INC. March 31, 2021Exclusive License and Collaboration Agreement • May 13th, 2021 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive License and Collaboration Agreement (this “Agreement”), dated as of March 31, 2021 (the “Execution Date”), is entered into by and between Cidara Therapeutics, Inc., a Delaware corporation, having an address of 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 (“Cidara”), and Janssen Pharmaceuticals, Inc., a corporation organized and existing under the laws of Pennsylvania, with its principal business office located at 1125 Trenton-Harbourton Road, Titusville, NJ 08560 (“Janssen”). Cidara and Janssen are each sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT by and among BEIGENE, LTD. and CELGENE CORPORATION and CELGENE SWITZERLAND LLC Originally executed on July 5, 2017, and entered into as of August 31, 2017Exclusive License and Collaboration Agreement • November 13th, 2017 • BeiGene, Ltd. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of August 31, 2017 (the “Amended Execution Date”) and made effective as of the Effective Date (as defined in Section 15.2) by and among BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands (“BeiGene”), and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations of Celgene under this Agreement in the United States (subject to Section 14.16), and Celgene Switzerland LLC, a Delaware limited liability company (“Celgene LLC”), with respect to all rights and obligations of Celgene under this Agreement outside of the United States (subject to Section 14.16) (Celgene Corp. and Celgene LLC together, “Celgene”). Celgene and BeiGene are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.
March 5, 2020Exclusive License and Collaboration Agreement • March 6th, 2020
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • May 11th, 2015 • Oncothyreon Inc. • Services-commercial physical & biological research • New York
THIS EXCLUSIVE AND COLLABORATION LICENSE AGREEMENT (this “Agreement”) dated as of April 16, 2014 (the “Effective Date”), is entered into between Sentinel Oncology Limited (“Licensor”), having a place of business at 23 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0EY, and Oncothyreon Inc., a Delaware corporation (“Company”), having a place of business at 2601 Fourth Ave., Suite 500, Seattle, WA 98121, USA, each a “Party” and collectively “Parties”.
